FiercePharmaAsia—China’s drug leader crackdown; Astellas’ gene therapy deal; Huahai’s problems

17th August 2018 Uncategorised 0

China’s former FDA chief resigns from his leadership role at the new market regulatory agency over the latest vaccine scandal; Astellas buys U.K. gene therapy developer Quethera for $109 million; and the FDA found quality-control problems at Zhejiang Huahai Pharmaceutical a year ahead of the valsartan recall.

More: FiercePharmaAsia—China’s drug leader crackdown; Astellas’ gene therapy deal; Huahai’s problems
Source: fierce